Eris Lifesciences Ltd · NSE:ERIS

Eris Lifesciences — FY2018 Earnings Presentation

15 slides from Eris Lifesciences's earnings presentation, March 2018

  1. Slide 1: Q4 18 and FY18 Investor Presentation

    Q4 18 and FY18 Investor Presentation

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions

  3. Slide 3: Contents

    CONTENTS PATIENT ENGAGEMENT MODEL BRAND FOCUS 1 STRONG FUNDAMENTALS MARKET FOCUS YIELD PER MAN ENHANCED FOOTPRINT 2 GROWTH PROSPECTS THERAPY AREA FOCUS 3 RESULTS FINANCIAL PERFORMANCE

  4. Slide 4: Patient Engagement Model

    STRONG FUNDAMENTALS PATIENT ENGAGEMENT MODEL IMPROVING HEALTH OUTCOMES PATIENT ENGAGEMENT – the core of our business model. The aim is to improve health outcomes and the doctor – patient relationship with detailed data Identifying gaps in the healthcare delivery ecosystem and addressing those gaps w

  5. Slide 5: Brand Focus – High Market Share for Our Top 15 Brands

    STRONG FUNDAMENTALS BRAND FOCUS – HIGH MKT SHARE FOR OUR TOP 15 BRANDS (Market share - FY 18) Sales Val FY 18 (INR Mn) (Prescription rank FY 18) (CAGR FY 13-18) GLIMISAVE 5.5% 1835 #3 24.4% ERITEL 4.9% 1023 #4 22.3% RENERVE 6.4% 801* #3 15.5% TAYO 4.6% 530 #5 6.5% RABONIK 3.8% 477 #12 4.6% OLMIN 6.3

  6. Slide 6: Brand Focus – Small Tail and High Growth Brands

    STRONG FUNDAMENTALS BRAND FOCUS – SMALL TAIL AND HIGH GROWTH BRANDS ERIS Top 15 Mother brands revenue contribution 73% Growth brands IPM Top 25 Co Mature brands 59.0% Avg Decline brands 25% Eris 74.2% 2% Top 25 mother brands revenue contribution 39% 31% 29% IPM Top 25 Co Avg 70.5% Eris IPM 83.7%  F

  7. Slide 7: Market Focus

    STRONG FUNDAMENTALS MARKET FOCUS STRONG PRESENCE IN REPRESENTED MARKET Segment mix REPRESENTED MARKET SHARE RANKING MARKET 37.6% CARDIOLOGY INR 82 BILLION 3.3% 10 65.2% ANTI Acute INR 56 BILLION 4.7% 7 DIABETES 62.4% VMN INR 40 BILLION 4.9% 3 34.8% 1.8X Chronic INR 56 BILLION IPM Eris GASTRO 1.5% 18

  8. Slide 8: Yield Per Man – Consistent Growth

    STRONG FUNDAMENTALS YIELD PER MAN – CONSISTENT GROWTH Number Of MRs YPM in INR LACS 4.16 4.3 1,970 3.50 3.6 1,679 1,436 1,499 1,422 1,501 2.95 3.03 2.75 1,192 FY 13 FY 14 FY 15 FY 16 FY 17 H1 18 FY 18 FY 13 FY 14 FY 15 FY 16 FY 17 H1 18 FY 18 Slight dilution in YPM metric for 31 Mar ’18 is due to ex

  9. Slide 9: Enhanced Footprint – FY17 to FY18

    GROWTH PROSPECTS ENHANCED FOOTPRINT – FY 17 to FY 18 Eris Covered Market FY 18 Eris Covered Market FY 17 INR 394 billion Grew by 35% to… INR 531 billion = 35% of IPM = 44% of IPM Number of MRs Number of MRs Grew by 469 to… 1,501 1,970 Source : IMS TSA MAT Mar 17 , IMS TSA MAT Mar 18 & Company intern

  10. Slide 10: Therapy Area Focus

    GROWTH PROSPECTS THERAPY AREA FOCUS While therapy areas like Cardiac and Diabetes continue to remain strong focus areas, we envisage these TAs as a large part of the next phase of our growth ….. Added 2 new divisions Covered Market increased CNS The acquisition of the Strides portfolio added to 171%

  11. Slide 11: Financial Performance: FY18

    RESULTS FINANCIAL PERFORMANCE: FY 18 Q4 2,122 FY18 8,556 Revenue from Operations 1,837 7,495 Q4 17 Q4 18 FY 17 FY 18 YoY Growth 15.5% 14.1% 3,220 717 EBIDTA 490 2,691 Q4 17 Q4 18 FY 17 FY 18 YoY Growth 46.3% 19.7% 2,941 PAT 558 2,468 472 Q4 17 Q4 18 FY 17 FY 18 YoY Growth 18.0% 19.2% All figures in

  12. Slide 12: Financial Performance: FY13-18

    RESULTS FINANCIAL PERFORMANCE: FY 13 - 18 Revenue from Operations EBITDA 8,556 7,495 3,220 CAGR- 17% 5,970 CAGR- 30% 2,691 5,088 5,456 3,931 1,715 989 1,215 859 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 PAT EPS 21.39 2,941 17.95 CAGR- 38% 2,468 CAGR- 38% 1,336 9.71 704

  13. Slide 13: Growth Credentials / Key Ratios: FY13-18

    RESULTS GROWTH CREDENTIALS/ KEY RATIOS: FY 13 - 18 ROE ROCE 131% 171% 106% 96% 94% 139% 128% 83% 110% 99% 61% 39% FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 ROE: PAT after minority and share of associates / Net worth (ex-cash) ROCE (RETURN ON CAPITAL EMPLOYED) : Net wort

  14. Slide 14: Shareholding Pattern as on 31st Mar 2018

    Shareholding Pattern as on 31st Mar 2018 Top 10 Institutional Shareholders Shareholding Pattern as on 31st Mar 2018 Birla Sun Life Trustee Company 3.27% 8.6% 0.8% Motilal Oswal Mutual Fund 3.14% 10.3% Goldman Sachs India Ltd 1.59% SBI Mutual Fund 1.4% 55.9% Morgan Stanley 1.39% 24.4% Matthews India

  15. Slide 15: Thank You

    Eris THANK YOU

Eris Lifesciences — FY2018 Earnings Presentation on 6ix